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Objective: Armodafinil is the R-enantiomer of racemic modafinil and has a significantly
longer half-life than the S-enantiomer. This study evaluated armodafinil 150mg/day as an
adjunct treatment for residual excessive sleepiness in patients with obstructive sleep
apnea/hypopnea syndrome (OSA/HS) who were otherwise well controlled with nasal
continuous positive airway pressure (nCPAP). We assessed the ability of armodafinil to
improve wakefulness and cognition and reduce fatigue in this population.
Methods: In this 12-week, randomized, double-blind study, patients (n ¼ 259) received
armodafinil (150mg) or placebo once daily. Efficacy assessments at baseline and weeks 4,
8, and 12 included the Maintenance of Wakefulness Test (MWT), Clinical Global Impression
of Change (CGI-C), Cognitive Drug Research battery, Epworth Sleepiness Scale, and Brief
Fatigue Inventory.
Results: At final visit, mean (SD) MWT sleep latency increased from baseline by 2.3
(7.8)min with armodafinil and decreased by 1.3 (7.1)min in the placebo group
(P ¼ 0.0003). Armodafinil improved clinical condition (CGI-C, 71% vs. 53% for armodafinil
and placebo, respectively; P ¼ 0.0069). Armodafinil significantly improved episodic
secondary memory (P ¼ 0.0102) and patient-estimated wakefulness (Po0.01) and reduced
fatigue (Po0.05) compared with placebo. Armodafinil did not adversely affect nCPAP use.
The most common adverse event associated with armodafinil was headache. Sleep
macroarchitecture was not altered by armodafinil.
Conclusion: Adjunct treatment with armodafinil significantly improved alertness, overall
clinical condition, and long-term memory. Armodafinil also reduced fatigue and the impactElsevier Ltd. All rights reserved.
7562; fax: 713 794 7558.
u (M. Hirshkowitz).
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Adjunct armodafinil in obstructive sleep apnea 617of sleepiness on daily activities in patients with OSA/HS who have residual excessive
sleepiness notwithstanding regular use of nCPAP. Armodafinil was well tolerated.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Obstructive sleep apnea/hypopnea syndrome (OSA/HS)
afflicts 7–20% of American adults.1 OSA/HS usually reduces
an individual’s overall functioning; is associated with
excessive sleepiness (ES), fatigue, and lack of energy; and
often adversely affects memory, concentration, and atten-
tion.2,3 Nasal continuous positive airway pressure (nCPAP) is
the standard of care for treating OSA/HS. It reduces
sleepiness,4,5 improves functioning,6 and improves self-
reported health status.4,7 However, some patients who
regularly use nCPAP experience residual ES.8 Studies have
shown that modafinil improves wakefulness in patients with
OSA/HS who have residual ES notwithstanding adequate
nCPAP use.9,10 Modafinil is the only drug currently approved
for the treatment of ES in this patient population.
Modafinil is a racemic compound containing equal
amounts of R-modafinil and S-modafinil. The R-enantiomer,
also known as armodafinil, has a half-life of 10–14 h
compared with 3–4 h for that of the S-enantiomer.11–13
Following chronic use of modafinil, the proportion of
circulating R-modafinil can be as much as three times
greater than that of circulating S-modafinil.11–13 Therefore,
most of the wakefulness maintenance effects of racemic
modafinil could theoretically be attributable to armodafinil.
This study assessed whether the therapeutically beneficial
effects of racemic modafinil for improving wakefulness9,10,14
could be replicated by administering armodafinil alone.
This randomized, double-blind, placebo-controlled study
assessed the efficacy and tolerability of armodafinil 150mg/
day as adjunct therapy to nCPAP for improving wakefulness
in patients with OSA/HS with residual ES notwithstanding
regular and effective nCPAP therapy.Methods
Patient selection
Eligible subjects included men and women, age 18–65 years,
who were diagnosed with OSA/HS15 and complained of
residual ES notwithstanding effective, regular, and adequate
use of nCPAP. The nCPAP criteria included stable therapy (for
at least 4 weeks); effective therapy (an apnea-hypopnea
index [AHI]p10 during overnight polysomnography); and
regular and adequate nCPAP use (X4 h per night on at least
70% of the nights during a 2-week evaluation period). A
Clinical Global Impression of Severity of illness16 rating of
X4 (corresponding to moderately ill or worse) and an
Epworth Sleepiness Scale (ESS)17 score of X10 were
required. Female patients of childbearing potential were
required to have a negative serum pregnancy test at
screening and use a medically accepted method of birth
control. Steroidal contraceptives had to be used in
conjunction with a barrier method.Individuals were excluded from the study if they had the
following: any clinically significant, uncontrolled psychiatric
or medical conditions that could account for their ES; a
probable or confirmed diagnosis of another sleep disorder
(other than OSA/HS); or any disorder that might interfere
with drug absorption, distribution, metabolism, or excretion
or produce daytime sleepiness. Other exclusion criteria
included pregnancy or lactation; consumption of 4600mg/
day of caffeine; history of alcohol or drug abuse18; medical
requirement for drugs disallowed by the protocol (modafinil,
melatonin, sodium oxybate, lithium, St. John’s wort,
methylphenidate, amphetamines, pemoline, antipsychotic
agents, benzodiazepines, zolpidem, monoamine oxidase
inhibitors, anticoagulants, anticonvulsants, and barbitu-
rates); use of clinically significant amounts of nonprescrip-
tion drugs within 7 days of the screening visit; use of
investigational drugs within 1 month of the screening visit;
or clinically significant drug sensitivity to stimulants or
modafinil. The study was conducted between March 26 and
October 23, 2004.Study design
This 12-week, randomized, double-blind, placebo-con-
trolled, parallel-group study was conducted in 36 centers
in the United States, Australia, Russia, Germany, and
France. The protocol was approved by an Independent
Ethics Committee or an Institutional Review Board at each
participating center. Furthermore, the study was conducted
according to international, national, and local laws and
regulations. Patients provided written informed consent.
Screening assessments included a 2-week period of at-home
nCPAP therapy using a REMstar Auto nCPAP System (Re-
spironics, Murrysville, PA) to assess adherence and nighttime
polysomnography to determine nCPAP effectiveness. The
REMstar Auto nCPAP device was used in CPAP mode. Patients
returned to the clinic for baseline assessments, randomiza-
tion, and drug dispensation and for postbaseline assessments
(weeks 4, 8, and 12) and nighttime polysomnography (week
12 only).
Patients meeting inclusion, exclusion, and screening
criteria were randomized (1:1) via an interactive voice
randomization system to receive armodafinil 150mg, for-
mulated as film-coated 50-mg tablets, or a matching
placebo. Because of the large number of planned centers,
randomization was stratified by country. Patients assigned to
armodafinil received 50mg on the first day followed by an
additional 50mg/day for two consecutive days, with the
final dosage reached on day 4. Patients assigned to placebo
were titrated in the same manner. Study drug was packaged
in child-resistant blister cards. At home, patients took study
drug once daily in the morning before 0800 h, approximately
30min before breakfast. On clinic days, study drug was
taken at approximately 0700 h. Patients and investigators
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each center, the investigator was responsible for monitoring
patient compliance. Compliance checks included comple-
tion of study drug accountability records and reviews of
patient diaries.Assessments
Efficacy assessments were performed at screening or base-
line and at weeks 4, 8, and 12. The Maintenance of
Wakefulness Test (MWT), an objective measure of wakeful-
ness that uses polysomnography to verify a patient’s ability
to remain awake19 was conducted as 30-min tests scheduled
at 0900, 1100, 1300, 1500, 1700, and 1900. The use of 20-,
30-, and 40-min sessions has been reported previously.19–22
In this study, 30-min tests were conducted to minimize the
potential for a ceiling effect with regard to the objective
level of ES in these nCPAP-treated patients with OSA/HS and
to accommodate the timely administration of all the
assessments used in the study. Sleep latency was defined
as the time to onset of the first of three consecutive epochs
of stage 1 sleep or the time to onset of any epoch of stages
2, 3, and 4, or rapid eye movement sleep.23 Individuals
falling asleep during a testing session were awakened but
required to remain in bed and were prevented from falling
asleep for the remainder of the 30-min test session. Patients
who did not fall asleep during a test session were assigned a
sleep latency of 30min. To distinguish between earlier and
later effects, MWT sleep latencies were averaged across the
first 4 (0900, 1100, 1300, and 1500) and the last 3 (1500,
1700, and 1900) tests.
The Clinical Global Impression of Change (CGI-C) assessed
changes from baseline in overall clinical condition. For the
CGI-C, seven categories ranging from ‘‘very much im-
proved’’ to ‘‘very much worse’’ were completed by the
investigators.16
The Cognitive Drug Research (CDR) battery, a computer-
ized battery of tests that assesses changes in cognitive
function,24,25 was administered at 0930, 1130, 1330, 1530,
1730, and 1930. The CDR battery included tests of memory
(i.e., numeric working memory, word recognition, immedi-
ate word recall, delayed word recall, and picture recogni-
tion) and attention (i.e., simple reaction time, choice
reaction time, and digit vigilance task). The entire battery
of tests took approximately 25min to complete. Composite
factors derived from the CDR included quality of episodic
secondary memory, which measures the ability to store and
retrieve information while not actively rehearsing the
information; speed of memory, which assesses the time it
takes to decide whether an item is held in memory; power of
attention, which measures the ability to focus attention and
avoid distraction; and continuity of attention, which
measures the ability to sustain concentration. CDR factor
scores were averaged across the first 4 (0930, 1130, 1330,
and 1530) and the last 3 (1530, 1730, and 1930) tests.
At each visit, the ESS and Brief Fatigue Inventory (BFI)
were assessed. The ESS, a subjective measure of the extent
to which ES interferes with daily activities, assessed changes
from baseline in patient-estimated sleepiness.17 Total scores
range from 0 to 24, with higher scores indicating greater
sleepiness. The BFI, a 9-item questionnaire that assesses theseverity and impact of fatigue on daily functioning,26 was
used to assess patient-rated fatigue based on changes in
global fatigue (average of all questions) and worst fatigue
during the past 24 h (item number 3). It uses a numeric
rating scale ranging from 0 to 10, with higher scores
corresponding to greater fatigue. Both the ESS and BFI were
administered before the first MWT at each visit. Electronic
diaries were completed by patients and contained questions
related to sleepiness and recorded the number of unin-
tended sleep episodes, number of naps, and number of
mistakes/near misses/accidents. Diaries were distributed at
screening and reviewed at baseline and weeks 4, 8, and 12.
Primary efficacy variables included the change from
baseline to final visit (week 12 or termination) in mean
MWT sleep latency averaged across the first 4 tests and the
proportion of patients with at least minimal improvement on
CGI-C, as related to clinical condition, at the final visit
(week 12 or termination). Secondary efficacy assessments
included changes in MWTsleep latencies averaged across the
last 3 tests, CDR factor scores, ESS total scores, and BFI
scores (global and worst fatigue). All efficacy assessments
were analyzed at weeks 4, 8, and 12 (using observed cases)
and at final visit (using last observation carried forward).
Adverse events were monitored throughout the study,
with severity and the relationship to study drug provided by
the investigator. Clinical laboratory tests (chemistry, hema-
tology, urinalysis), vital sign measurements, and electro-
cardiograms were performed at screening, baseline, and
weeks 4, 8, and 12. Vital signs were assessed at approxi-
mately 3 and 13 h post study drug administration. Physical
examinations were conducted at screening, baseline, and
week 12. To assess whether armodafinil adversely affected
nighttime sleep, polysomnography 23 was conducted for 8 h,
starting within 30min of the patient’s habitual bedtime but
no earlier than 2130, at screening, and at week 12 (after the
daytime MWT). Nasal CPAP use was objectively monitored at
least 2 weeks before baseline and throughout the study.Statistical analysis
A sample size of 108 patients per treatment group was
required to provide at least 80% power to detect a 2.5-min
difference in the MWT mean sleep latency, assuming a
common SD of 6.5min, and a 25% difference in the
proportion of patients reporting at least minimal improve-
ment in CGI-C ratings, assuming 36% improvement in the
placebo group. An enrollment of approximately 240 patients
was planned to obtain 216 evaluable patients with at least 1
postbaseline MWT and CGI-C assessment.
Descriptive statistics were used to summarize continuous
and categorical demographic variables. Continuous demo-
graphic variables were compared between groups using
analysis of variance (ANOVA), with treatment group as a
factor. Categorical demographic variables were compared
using Pearson’s w2 test or Fisher exact test. Efficacy analyses
included randomized patients who received at least 1 dose
of study drug and had a baseline measurement and at least 1
postbaseline measurement on the MWT and at least 1
assessment on the CGI-C. All continuous efficacy variables
was analyzed using ANOVA, with treatment and country
as factors and pairwise comparisons performed using
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analyzed using a Cochran–Mantel–Haenszel w2 adjusted for
country; pairwise comparisons were performed using the
appropriate subsets. All tests of treatment effect were
2-sided and performed at the 0.05 significance level. Change
from baseline to the final visit for data from patient diaries
and vital signs was analyzed using the nonparametric test of
Wilcoxon. The change in nCPAP use from baseline to on-
treatment values was analyzed using a 1-way ANOVA with
treatment as factors. Data from nighttime polysomnography
were summarized using descriptive statistics. Safety ana-
lyses included all randomized patients who received at least
1 dose of study drug.Results
Patients
Of 466 patients screened for the study, 263 (armodafinil,
n ¼ 131; placebo, n ¼ 132) were randomized, and 259
(armodafinil, n ¼ 129; placebo, n ¼ 130) received study
drug. Patient characteristics were comparable between the
groups (Table 1). With respect to illness severity, 57% of
patients were rated by the investigator(s) as moderately ill,
with the remaining 43% rated as markedly, severely, orTable 1 Baseline/Screening Demographics.
Characteristic Placebo
Mean (SD) age, y 50.6 (8
Range 25–68
Sex, n (%)
Men 93 (72)
Race, n (%)
White 111 (85)
Other 18 (14)
Missing 1 (o1
Mean (SD) BMI, kg/m2 30.8 (7
CGI-S, n (%)y
Moderately ill 75 (58)
Markedly ill 39 (30)
Severely ill 13 (10)
Among the most extremely ill 3 (2)
Mean (SD) ESS total scorey 16.0 (3
nCPAP, h/nightz 6.9 (1
Mean (SD) MWT sleep latencyy 23.3 (8
AHI at baseline during nCPAPz 1.4 (2
AHI ¼ apnea-hypopnea index; BMI ¼ body mass index; CGI-S ¼ Cli
Sleepiness Scale; MWT ¼ Maintenance of Wakefulness Test; nCPAP ¼ n
As exceptions to the protocol, 1 patient receiving placebo and 2 pa
of age.
yAt screening. ESS scores are for 120 patients receiving placebo and
pathologic sleepiness.
zNasal CPAP data are for 126 patients receiving placebo and 128 p
yMWT sleep latencies were averaged across the first 4 sessions (09
placebo and 116 patients receiving armodafinil 150mg/day.
zAHI data are for 129 patients receiving placebo and 125 patientsextremely ill. Patients experienced ES before the start of
the double-blind phase (as shown by mean ESS total scores
of 15.6 and 16.0 for the armodafinil and placebo groups,
respectively) notwithstanding a high mean duration of
nightly nCPAP therapy of approximately 7 h and low mean
AHI indices. At baseline, mean sleep latency on the MWTwas
similar between the groups. In accordance with entry
criteria, patients were receiving effective nCPAP therapy
before receiving armodafinil or placebo (mean [SD] AHI,
armodafinil, 1.1 [2.1]; placebo, 1.4 [2.3]). One hundred
fifty-three patients (59%) had a medical history of cardio-
vascular disease. Cardiovascular disease included hyperten-
sion, n ¼ 102 (39%); arrhythmias, n ¼ 11 (4%); chest pain,
n ¼ 13 (5%); congestive heart failure, n ¼ 1 (o1%); and
other, n ¼ 88 (34%).
Two hundred twenty-nine patients (armodafinil, n ¼ 111;
placebo, n ¼ 118) (87%) completed the study. Twenty
patients (15%) randomized to armodafinil discontinued the
study for the following reasons: adverse event (n ¼ 5),
consent withdrawn (n ¼ 5), noncompliance with study
procedures (n ¼ 3), protocol violation (n ¼ 2), loss to
follow-up (n ¼ 2), other (n ¼ 2), and insufficient efficacy
(n ¼ 1). Fourteen patients (11%) randomized to placebo
discontinued the study for the following reasons: adverse
event (n ¼ 6), consent withdrawn (n ¼ 3), protocol violation
(n ¼ 3), and loss to follow-up (n ¼ 2).n ¼ 130 Armodafinil 150mg n ¼ 129
.9) 50.7 (9.2)
27–69
97 (75)
107 (83)
22 (17)
) 0 (0)
.5) 36.3 (7.8)
72 (56)
37 (29)
18 (14)
2 (2)
.5) 15.6 (3.5)
.0) 6.8 (1.3)
.2) 23.7 (8.6)
.3) 1.1 (2.1)
nical Global Impression of Severity of Illness; ESS ¼ Epworth
asal continuous positive airway pressure; SD ¼ standard deviation.
tients receiving armodafinil 150mg/day were older than 65 years
115 patients receiving armodafinil 150mg/day. ESSX10 indicates
atients receiving armodafinil 150mg/day.
00, 1100, 1300, and 1500). Data are for 120 patients receiving
receiving armodafinil 150mg/day.
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MWT Sleep Latency
Armodafinil significantly improved wakefulness compared
with placebo (Fig. 1A). At the final visit, the mean (SD) MWT
sleep latency across the first 4 tests (0900, 1100, 1300, and
1500) increased from baseline by 2.3 (7.8) min in the
armodafinil group and decreased by 1.3 (7.1) min in the
placebo group (P ¼ 0.0003). Armodafinil significantly im-
proved MWT sleep latency compared with placebo at each
visit (all Po0.01).
Significant improvement in mean sleep latency across the
last 3 tests (1500, 1700, and 1900) was shown for the
armodafinil group (mean [SD] change, 1.8 [9.6] min) versus
the placebo group (mean change, –0.5 [6.3]min) at week 12
(P ¼ 0.0435; Fig. 1B). Armodafinil improved mean sleep
latency to a similar extent at the final visit and weeks 4 andWeek 4 Week 8−3
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Figure 1 Mean changes from baseline in sleep latency on the Maint
the first 4 tests (0900, 1100, 1300 and 1500). At baseline, the mean
min for armodafinil 150mg/day. (B) Sleep latencies averaged across
(SEM) sleep latency was 24.2 (0.7) min for placebo and 24.5 (0.8) m8 (mean change ranged from 1.5–2.2min), but the differ-
ences did not achieve statistical significance versus placebo
(mean change ranged from 0.1 to 0.6min; P40.05). Over
the course of the day, numeric improvements in mean sleep
latency were seen for the armodafinil group compared
with the placebo group at final visit for all time points
(Fig. 2A and B).Clinical condition
Armodafinil significantly improved clinical condition com-
pared with placebo. At the final visit, the proportion of
patients with at least ‘‘minimal improvement’’ on the CGI-C
scale was significantly greater for armodafinil than placebo
(71% [82/116] vs. 53% [64/120]; P ¼ 0.0069). The proportion
of patients who were rated by the investigator as ‘‘veryWeek 12
Placebo
Armodafinil 150 mg/day
*
*
Final
sit
*
Week 12
Placebo
Armodafinil 150 mg/day
Final
isit
enance of Wakefulness Test. (A) Sleep latencies averaged across
(SEM) sleep latency was 23.3 (0.7) min for placebo and 23.7 (0.8)
the last 3 tests (1500, 1700, and 1900). At baseline, the mean
in for armodafinil 150mg/day.
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Figure 2 Sleep latencies at individual time points for (A)
armodafinil and (B) placebo.
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were 22% and 25%, respectively, in the armodafinil group
compared with 6% and 21%, respectively, in the placebo
group. Armodafinil significantly improved overall clinical
condition compared with placebo at each study visit (all
Po0.05).Cognitive Drug Research battery
Armodafinil significantly improved quality of episodic sec-
ondary memory compared with placebo. When averaged
across the first 4 tests (0930, 1130, 1330, and 1530), quality
of episodic secondary memory increased by 7.6 points from
baseline to the final visit for patients in the armodafinil
group and decreased by 7.0 points for those in the placebo
group (P ¼ 0.0102 for the change from baseline vs. placebo;
Fig. 3A). Significant improvement across the first 4 tests also
was shown at week 12 for the armodafinil group versus the
placebo group (P ¼ 0.005), with numeric differences in
favor of armodafinil observed at weeks 4 and 8. Numeric
improvements from baseline in quality of episodic secondary
memory across the last 3 tests (1530, 1730, and 1930) were
observed in the armodafinil group compared with the
placebo group; however, the difference versus placebo did
not achieve statistical significance (Fig. 3B). The numeric
improvements from baseline in speed of memory, continuity
of attention, or power of attention with armodafiniltreatment compared with placebo were not significant at
any study visit or at the final visit (P40.05).
Patient-reported wakefulness and reduction in
fatigue
Armodafinil significantly reduced the impact of ES on daily
activities. At final visit and each study visit, the mean
change from baseline in ESS total score was significantly
greater for patients receiving armodafinil than for those
receiving placebo (all Po0.01; Fig. 4A). Armodafinil
significantly reduced global fatigue and worst fatigue in
the past 24 h at weeks 4 and 12 and at the final visit
compared with placebo (all Po0.05; Fig. 4B and C).
Diary data for daytime sleepiness
Significant differences were shown between the armodafinil
and placebo groups in the number of unintended sleep
episodes and number of daily naps. At baseline, the mean
(SD) number of unintended sleep episodes was 1.0 (1.1) for
the armodafinil group and 1.2 (1.2) for the placebo group.
Post baseline, the percentage decrease from baseline in the
number of unintended sleep episodes was 54.7% and 37.1%,
respectively (overall treatment comparison, P ¼ 0.0002).
The mean (SD) number of daily naps at baseline was 0.5 (0.5)
for the armodafinil group and 0.5 (0.5) for the placebo
group. Post baseline, the percentage decrease from baseline
was 35.7% and 17.0%, respectively (overall treatment
comparison, P ¼ 0.0016). No statistically significant differ-
ences were observed between the armodafinil and placebo
groups in the number of mistakes/near misses/accidents
(percentage change from baseline, 29.2% and –12.8% for
armodafinil and placebo, respectively). Caffeine use was
comparable across all groups.
Safety outcomes
Headache, nausea, diarrhea, dizziness, and anxiety were
the most frequently reported adverse events (X5%) in
patients who received armodafinil (Table 2). Adverse events
were generally mild or moderate in nature. No patients
receiving armodafinil experienced a serious adverse event; 1
patient receiving placebo experienced serious gastroeso-
phageal reflux. Four percent (5/129) of patients randomized
to armodafinil discontinued the study because of an adverse
event compared with 5% (6/130) of patients receiving
placebo. Rash was the most frequent adverse event leading
to discontinuation (armodafinil, n ¼ 2; placebo, n ¼ 1).
There were no clinically meaningful changes from base-
line to final visit in either group for laboratory values, vital
sign measurements, electrocardiographic parameters, or
physical examination findings. Small mean increases from
baseline to the final visit in gamma-glutamyl transpeptidase
(armodafinil, 6.6 [11.2] U/L vs. placebo, 0.6 [12.8] U/L) and
alkaline phosphatase (2.3 [9.7] U/L vs. –1.1 [9.4] U/L)
observed in patients receiving armodafinil compared with
those receiving placebo were not considered clinically
meaningful. There were no statistically or clinically mean-
ingful changes in systolic and diastolic blood pressure or
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Figure 3 Mean changes from baseline in quality of episodic secondary memory on the Cognitive Drug Research battery. (A) Scores
were averaged across the first 4 tests (0930, 1130, 1330, and 1530). At baseline, the mean (SEM) episodic memory score was 161.9
(4.0) units for placebo and 172.4 (3.7) units for armodafinil 150mg/day. (B) Scores were averaged across the last 3 tests (1530, 1730,
and 1930). At baseline, the mean (SEM) episodic memory score was 150.5 (4.2) units for placebo and 162.6 (3.8) units for armodafinil
150mg/day.
M. Hirshkowitz et al.622pulse. There were no qualitative differences in electro-
cardiography findings between armodafinil and placebo.
The duration of nCPAP therapy was high in both groups,
approximately 7 h per night before the start of study drug,
and remained high during the study. The mean (SD) duration
of nCPAP decreased slightly from the baseline to postbase-
line period for the armodafinil (–0.2 [0.7]) and placebo (–0.2
[0.6]) groups. This small decrease in nCPAP use was not
accompanied by an increase in the AHI in either group (mean
change from baseline, armodafinil, 0.1 [1.4] vs. placebo, 0.2
[2.9]).
Armodafinil had no adverse effects on nighttime sleep as
determined by subjective and objective measures. Mean (SD)
sleep efficiency from patient diaries increased by 2.6% (4.4)
and 2.0% (5.2), and mean sleep latency decreased by 5.8
(12.7) and by 4.1 (9.2) min for the armodafinil and placebo
groups, respectively. No clinically meaningful changes inpolysomnographically defined sleep parameters were seen
in either group (Table 3).Discussion
Excessive sleepiness is a serious condition that is often
undiagnosed.27 It is associated with high morbidity and
affects not only patients but also their families, coworkers,
and the public at large. The true prevalence of residual ES in
OSA/HS patients who use nCPAP is not known, and the
mechanisms that underlie residual sleepiness in these
patients are poorly defined. Possible explanations include
chronic partial sleep loss from sleeping less than 8 h per
night, fragmented sleep caused by persistent nighttime
arousals, and alterations in sleep architecture that lead to
less-than-adequate sleep. Alternatively, hypoxia-induced
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Figure 4 Mean changes from baseline in patient-reported wakefulness and fatigue. (A) Epworth Sleepiness Scale total score. At
baseline, total scores were 16.0 (0.3) for placebo and 15.6 (0.3) for armodafinil 150mg/day. (B) Global fatigue score. At baseline,
scores were 4.9 (0.2) for placebo and 4.7 (0.2) for armodafinil 150mg/day. (C) Worst fatigue in the past 24 h score. At baseline,
scores were 7.1 (0.2) for placebo and 7.0 (0.2) for armodafinil 150mg/day.
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upper airway abnormalities, suboptimal quantity or quality
of sleep arising from subtherapeutic nCPAP, or suboptimal
sleep induced by nCPAP may be contributing factors.28
Interestingly, residual ES can be present even when sleep
fragmentation and hypoxemia are well treated in patients
who adhere strictly to nCPAP therapy.8 Regardless of the
underlying cause, recognition and management of ES is
critical given its adverse effects on cognitive, occupational,
and social functioning.29
By selection, patients in this study adhered well to nCPAP
therapy and used it for an adequate duration but still
reported ES. Inclusion criteria were based on a substantive
complaint of ES, which was verified by the ESS. Nonetheless,
some patients did not have substantial sleepiness at baseline
as determined by the objective MWT measures. Mean sleep
latency for normal controls has been reported to be
18.7(2.6) and 35.2(7.9) min on the 20- and 40-min MWT,Table 2 Adverse Events Occurring in X5% of Patients
Receiving Armodafinil or Placebo.
Adverse Event Number (%) of Patients
Placebo
n ¼ 130
Armodafinil
150mg n ¼ 129
Headache 9 (7) 19 (15)
Upper respiratory
tract infection
8 (6) 5 (4)
Nasopharyngitis 6 (5) 5 (4)
Nausea 4 (3) 6 (5)
Diarrhea 3 (2) 6 (5)
Dizziness 2 (2) 6 (5)
Anxiety 0 (0) 6 (5)
Includes randomized patients who received at least 1
dose of study drug.
Table 3 Polysomnographic Parameters for Patients Receiving A
Parameter Placebo
Baseline
Latency to persistent sleep, minz 23.3 (27.0)
Number of arousalsz 18.6 (9.9)
Number of awakeningsz 9.1 (5.6)
Sleep efficiency, %z 80.7 (14.0)
Wake after sleep onset (min)z 73.4 (57.8)
Sleep stage percentagez
Stage 1 11.1 (6.4)
Stage 2 59.4 (10.4)
Stage 3/4 10.9 (9.7)
REM 18.7 (7.8)
REM ¼ rapid eye movement.
Baseline: placebo, n ¼ 128; armodafinil, n ¼ 126.
yFinal visit: placebo, n ¼ 115; armodafinil, n ¼ 105.
zValues are the mean (SD).respectively.30 In the absence of normative data for a 30-min
test, it would be plausible to suggest that normal mean
sleep latency on a 30-min test would fall between these
values, perhaps around 25–26min. The mean sleep latency
at baseline on the 30-min MWT in this study was approxi-
mately 23min and may very well be representative of mild
to moderate sleepiness. Armodafinil administered once daily
significantly improved patients’ wakefulness as assessed by
the MWT and overall clinical condition compared with
placebo. These improvements were observed on the first
postbaseline visit, were maintained throughout the 12
weeks of the study, and were accompanied by improvements
in multiple patient-reported outcomes. Armodafinil reduced
fatigue, the extent to which ES interfered with daily
activities, and the number of naps and unintended sleep
episodes.
Previous studies9,10 did not evaluate the wake-promoting
effects of modafinil in the late afternoon in patients with
OSA/HS. Pharmacokinetic and pharmacodynamic results
with armodafinil and modafinil in healthy volunteers during
acute sleep loss show that a single dose of armodafinil
200mg helps sustain wakefulness and attention longer than
a single dose of modafinil 200mg.31 Thus, we anticipated in
the present study that armodafinil would improve late-day
alertness. Armodafinil significantly improved mean sleep
latency across the last 3 tests (1500–1900) at week 12
(P ¼ 0.0435). At final visit, the MWT sleep latency data at
late-day time points showed an expected diurnal increase in
wakefulness for both groups. Most of the between group
difference in mean sleep latency came at the 1500 test
session. Although armodafinil increased mean sleep latency
compared with placebo later in the day, the circadian-
related increase in wakefulness may have produced a ceiling
effect, thereby preventing discernment of a significant
difference between treatment groups during the individual
MWT measurements in the late afternoon and early evening.
Behavioral effects related to the last test of the day (last
nap effect) and high intertest variability in sleep latency
(i.e., three tests may have been insufficient to show armodafinil or Placebo.
Armodafinil 150mg
Finaly Baseline Finaly
24.4 (25.9) 21.6 (22.8) 19.1 (15.4)
18.8 (10.8) 20.0 (11.2) 18.4 (10.3)
9.7 (5.4) 8.8 (4.3) 9.6 (5.3)
79.6 (12.9) 81.9 (9.5) 81.9 (9.1)
74.2 (50.6) 70.5 (39.9) 71.5 (41.6)
11.3 (7.3) 11.2 (6.2) 10.4 (5.4)
57.0 (12.5) 59.7 (9.3) 58.1 (10.3)
11.2 (10.6) 10.9 (9.1) 11.3 (9.5)
20.5 (9.1) 18.2 (7.3) 20.1 (6.5)
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finding. Moreover, the study was powered to detect
the difference in treatment effect for the first 4 test
sessions.
The etiology of diminished cognitive functioning in
patients with OSA/HS is unknown. One hypothesis blames
chronic intermittent hypoxia.32–34 However, some reports
indicate nCPAP-related improvement in memory and atten-
tion in patients with OSA/HS, whereas others have docu-
mented reduced sleepiness without improved
cognition.5,33–36 Findings from the CDR indicate that
armodafinil significantly improved long-term memory (qual-
ity of episodic secondary memory) at final visit compared
with placebo. The factor score for quality of episodic
secondary memory combined the accuracy measures of 4
classical tests of memory: immediate word recall, delayed
word recall, word recognition, and picture recognition.
Significant improvements in this score were seen at week 12
and final visit, reflecting greater ability to store and retrieve
verbal and pictorial information in episodic memory. These
data indicate that memory function can be improved in this
clinical group by armodafinil. A previous study of healthy
volunteers undergoing a period of acute sleep loss has
reported that armodafinil and modafinil showed similar
ability to sustain attention on the Psychomotor Vigilance
Task when administered at similar doses.31 Because indirect
comparisons across studies are speculative, a head-to-head
study of armodafinil and modafinil would be needed to
directly assess cognitive effects of the two compounds in a
population with ES.
When ES is present, patients often report fatigue,
tiredness, and lack of energy rather than sleepiness.37 Data
from the current study show that, on average, patients with
OSA/HS experienced severe fatigue at baseline even with
adequate nCPAP therapy, as shown by a mean score of 47
for the BFI worst fatigue item.26 Armodafinil significantly
reduced symptoms of fatigue for the duration of the study.
Armodafinil was generally well tolerated, with most
adverse events rated as mild to moderate in severity. The
rate of study discontinuations attributable to adverse events
was low and comparable to that shown with placebo.
Armodafinil, taken once daily in the morning, had no
adverse effect on the quality or quantity of nighttime sleep.
The magnitude of change in the nightly duration of nCPAP
use was relatively small, and nCPAP use remained high (i.e.,
at approximately 7 h per night), with no effect on arousals.
In other studies, average nightly use of nCPAP has been
reported to range from 5 to 6.5 h.38 Although more than half
of the study population had cardiovascular disease and more
than one third of patients had hypertension at baseline,
treatment with armodafinil was not associated with adverse
cardiovascular effects. Previous studies with racemic mod-
afinil also failed to show heart rate and blood pressure
alterations.9,10 This is noteworthy because untreated OSA/
HS is an independent risk factor for heart disease39 and
systemic hypertension.40,41
The relatively short duration of treatment in this study
limits generalizability to long-term clinical use. The study
was conducted in patients who were receiving regular nCPAP
therapy yet had residual ES. These findings should not be
generalized to OSA/HS patients who are not receiving
therapeutic nCPAP. Armodafinil does not treat the under-lying obstruction and is not a replacement for nCPAP
therapy.
In summary, once-daily administration of armodafinil
150mg/day improved patients’ wakefulness and overall
clinical condition when used as adjunct therapy for residual
ES associated with OSA/HS in patients who regularly use
nCPAP therapy. Further research is warranted to follow up
on findings that armodafinil may improve long-term memory.
Additional studies should explore whether the reduction in
fatigue seen with armodafinil in this study affects daytime
functioning and quality of life in this population. These
results support using armodafinil to treat residual ES in
patients with OSA/HS who adhere to nCPAP therapeutic use
prescription, who are properly titrated to an effective
pressure, and who maintain an adequate sleep schedule.Acknowledgment
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